Press Releases
Date Title and Summary View
May 7, 2012 New York (May 7, 2012) – Retrophin, LLC, a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced completion of its Series A financing. The $4 million round was led by MSMB Capital. The company intends to invest the proceed...
Feb 21, 2012 San Diego and New York (February 21, 2012) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Retrophin, LLC announced that the companies have entered into an agreement in which Ligand has licensed rights to DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors) to R...
Page: FirstPrevious ...
14
= add release to Briefcase